These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Clinical applications of hypoglycemic and antidiabetic drugs]. LANDABURE PB Dia Med; 1956 Jun; 28(40):1100-6. PubMed ID: 13344290 [No Abstract] [Full Text] [Related]
23. The value of BZ 55 in control of diabetes. MURRAY I; WANG I Br Med J; 1956 Aug; 2(4990):452-4. PubMed ID: 13342512 [No Abstract] [Full Text] [Related]
24. [Critical study of the mechanism of action of the oral anti-diabetic agent, nadisan]. FRAENKEL KA; SCHULZ K Dtsch Med J; 1956 Apr; 7(8):209-14. PubMed ID: 13344175 [No Abstract] [Full Text] [Related]
25. [Ambulatory treatment of diabetics with a hypoglycemic sulfonamide]. RAMEL C; HOFSTETTER JR Praxis; 1956 Apr; 45(16):365-9. PubMed ID: 13335688 [No Abstract] [Full Text] [Related]
26. [Antidiabetic effect of a new sulfonamide]. TOLOMELLI E; PELLEGRINI R; POPPI A Riforma Med; 1956 Feb; 70(7):180-3. PubMed ID: 13311263 [No Abstract] [Full Text] [Related]
27. [The Langerhans islands of diabetics after treatment with the oral antidiabetic, BZ 55]. FERNER H; RUNGE W Dtsch Med Wochenschr; 1956 Mar; 81(10):331-3. PubMed ID: 13317606 [No Abstract] [Full Text] [Related]
28. [Treatment of diabetes mellitus with hypoglycemic sulfonamides]. BOULIN R Gaz Med Fr; 1957 Mar; 64(6):545-53. PubMed ID: 13427960 [No Abstract] [Full Text] [Related]
29. BZ-55 (CARBUTAMIDE): experimental and clinical studies of an oral antidiabetic agent. Can Med Assoc J; 1956 Jun; 74(12):957-98. PubMed ID: 13329939 [No Abstract] [Full Text] [Related]
31. [A new antidiabetic sulfamide; clinical indications and dosage]. RAVINA A Presse Med (1893); 1956 Apr; 64(28):646-9. PubMed ID: 13335855 [No Abstract] [Full Text] [Related]
32. Tolbutamide in treatment of diabetes mellitus. BUTTERFIELD WJ; FRY IK; HARDWICK C; HOLLING HE Br Med J; 1957 Aug; 2(5040):325-7. PubMed ID: 13446469 [No Abstract] [Full Text] [Related]
33. [A new anti-diabetes principle; results of clinical research]. FRANKE H; FUCHS J Dtsch Med Wochenschr; 1955 Oct; 80(40):1449-52. PubMed ID: 13261731 [No Abstract] [Full Text] [Related]
34. The relation of various variables to the hypoglycemic action of 1-butyl-3-p-tolylsulfonylurea in patients with diabetes mellitus. DIENGOTT D; DOLGER H; MIRSKY IA Metabolism; 1956 Nov; 5(6 Part 2):875-93. PubMed ID: 13378057 [No Abstract] [Full Text] [Related]
35. The mechanism of action of the sulfonylureas in diabetes mellitus. LEVINE R; SOBEL GW Diabetes; 1957; 6(3):263-9. PubMed ID: 13427633 [No Abstract] [Full Text] [Related]
36. Clinical use of oral sulfonylurea compounds in diabetes mellitus. COLWELL AR; COLWELL JA Q Bull Northwest Univ Med Sch; 1957; 31(2):102-13. PubMed ID: 13453644 [No Abstract] [Full Text] [Related]
37. [Treatment of ten cases of diabetes with oral hypoglycemic sulfonamide BZ 55 or nadisan]. FERNANDEZ BASABE E; GALAN J; OLIVER A; OLIVER-PASCUAL E; PURAS E Rev Esp Enferm Apar Dig Nutr; 1956; 15(2):478-88. PubMed ID: 13370980 [No Abstract] [Full Text] [Related]
38. [BZ-55, a peroral antidiabetic remedy with a possible glucagon-restraining effect]. ANDERSSON B Sven Lakartidn; 1956 Jan; 53(2):57-64. PubMed ID: 13311777 [No Abstract] [Full Text] [Related]
39. Hypoglycaemic and anti-diabetic sulphonamides. YOUNG FG Br Med J; 1956 Aug; 2(4990):431-2. PubMed ID: 13342506 [No Abstract] [Full Text] [Related]